Good morning. Should Peter be able to give the final rose to a woman competing on the show this season, and to a woman who is not competing this season but has clearly stolen his heart?
Today's word count is 665 words, or a 3-minute read.
Illustration: Sarah Grillo/Axios
Most people don't have nearly as much choice over their health insurance plans as Republicans and moderate Democrats sometimes suggest.
Between the lines: People who get their insurance from their employer — the majority of people with private insurance — are often given few plans to choose from, if they're given any choice at all.
What they're saying: This came up in former Vice President Joe Biden's interview with the New York Times' editorial board:
The comment is a nod to how much control employers have over their employees' health insurance.
Biden has proposed a public insurance plan that would be open to people with employer-based insurance — which experts say could lead to some employers deciding not to offer their own coverage.
Between the lines: Framing choice as being about insurance "in many ways obscures the choice that probably ultimately matters to most people, which is choice of doctor or hospital," the Kaiser Family Foundation's Larry Levitt said.
It's not just Google — Amazon, IBM and Microsoft have also struck deals with hospitals across the country to gain access to patient data, the Wall Street Journal reports.
Why it matters: WSJ's reporting reveals just how expansive the relationship between tech companies and hospitals has become. And lawmakers have taken notice.
Details: There's no evidence of wrongdoing; hospitals can share patient data as long as they follow federal law.
The big picture: "Digitizing patients' medical histories, laboratory results and diagnoses has created a booming market in which tech giants are looking to store and crunch data, with potential for groundbreaking discoveries and lucrative products," WSJ writes.
CMS Administrator Seema Verma. Photo: Steven Ferdman/Getty Images
The Trump administration plans to issue guidance — potentially this month — on state waivers to change Medicaid funding into a block grant, WSJ scoops. (Bravo to the Journal's weekend health coverage.)
Why it matters: Some red states have already expressed interest in block grants, and supporters say they give states more flexibility, but consumer groups argue that they could lead to thousands of low-income people losing health coverage.
Yes, but: Like work requirements and several other pieces of the Trump administration's health agenda, block grants are likely to be challenged in court.
A generic version of Copaxone, one of the most popular drugs to treat multiple sclerosis, didn't do much to lower costs for patients, NPR reports.
The big picture: MS drugs cost $70,000 a year, on average, and some prices have increased to five times what they were when the drugs were first approved by the FDA.
The bottom line: "We've been, really been, looking to generics for some price relief, and we're probably not going to get it as quickly as we want," Stacie Dusetzina, a health policy professor at Vanderbilt University, told NPR.